AtriCure reports Q4 adjusted EPS 6c, consensus (11c)

Reports Q4 revenue $140.5M, consensus $139.78M. “Our 2025 performance reflects strong execution and continued momentum in our business. We delivered 15% revenue growth for the year and strengthened profitability while advancing key innovation and clinical initiatives, including enrollment of our LeAAPs clinical trial, and the initiation of our BoxX-NoAF trial, that position the company for sustained value creation,” said Michael Carrel, President and Chief Executive Officer at AtriCure (ATRC). “Entering 2026, we remain focused on driving durable growth, expanding margins and executing on strategic priorities that enhance AtriCure’s leadership position across our markets.”